(Q44100868)

English

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

scientific article published in August 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

nucleus accumbens

1 reference

based on heuristic

inferred from title

author name string

Jean-François Liégeois

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Junji Ichikawa

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Herbert Y Meltzer

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

1 August 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

947

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

157-165

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Catecholamine modulation of prefrontal cortical cognitive function

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The anxiolytic serotonin 5-HT1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

5-HT2 antagonism and EPS benefits: is there a causal connection?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Serotonin-dopamine interaction and its relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine, the prefrontal cortex and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

R(+)-8-OH-DPAT, a selective 5-HT(1A) receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Increased dopamine transmission in schizophrenia: relationship to illness phases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The dopamine hypothesis of schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The role of serotonin in antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

An atypical compound by any other name is still a

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Differential Effects of Dopamine Antagonists on Evoked Dopamine Release from Slices of Striatum and Nucleus Accumbens in Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Identifiers

10.1016/S0006-8993(02)02620-3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44100868&oldid=2106595513"